Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial

[1]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[2]  S. Marsch,et al.  Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study , 2009, European Respiratory Journal.

[3]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[4]  B. Bein,et al.  Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial , 2009, Critical care.

[5]  T. Fleming,et al.  Issues in noninferiority trials: the evidence in community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Gilbert,et al.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Briel,et al.  Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. , 2008, Archives of internal medicine.

[8]  A. Gascoigne,et al.  Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy , 2008, The Journal of antimicrobial chemotherapy.

[9]  A. Combes,et al.  Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia , 2008, Intensive Care Medicine.

[10]  J. Pugin,et al.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.

[11]  K. Becker,et al.  Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations , 2008, Critical care medicine.

[12]  Sean Keenan,et al.  Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. , 2008, Journal of critical care.

[13]  K. Colpaert,et al.  Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. , 2008, International journal of antimicrobial agents.

[14]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.

[15]  P. J. Z. Teixeira,et al.  Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. , 2007, The Journal of hospital infection.

[16]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[17]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[19]  M. Christ-Crain,et al.  Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.

[20]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[21]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[22]  C. Weenink,et al.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.

[23]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[24]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[25]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[26]  A. Combes,et al.  Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. , 2005, American journal of respiratory and critical care medicine.

[27]  A. MarioCalvo,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. Chastre J, Wolff M, Fagon JY, Chevret S et al. JAMA 2003; 290: 2588-98 , 2004 .

[28]  Marin H Kollef,et al.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.

[29]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[30]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[31]  Djillali Annane,et al.  Current epidemiology of septic shock: the CUB-Réa Network. , 2003, American journal of respiratory and critical care medicine.

[32]  X. Panhard,et al.  Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments , 2003, Antimicrobial Agents and Chemotherapy.

[33]  J. Quinn,et al.  Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.

[34]  J. Quinn,et al.  Antibiotic Resistance Among Gram-Negative Bacilli in US Intensive Care Units , 2003 .

[35]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[36]  D. Pittet,et al.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. , 2001, American journal of respiratory and critical care medicine.

[37]  M. Kollef,et al.  Antibiotic Resistance in the Intensive Care Unit , 2001, Annals of Internal Medicine.

[38]  Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials , 2001 .

[39]  T. Similowski,et al.  Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.

[40]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[41]  L E Nilsson,et al.  Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. , 1999, JAMA.

[42]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[43]  R A Weinstein,et al.  Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. , 1996, JAMA.

[44]  C. Sprung,et al.  The ACCP-SCCM consensus conference on sepsis and organ failure. , 1992, Chest.

[45]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[46]  R. Austrian,et al.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. , 1964, Annals of internal medicine.